Impact of New Systemic Therapies on Overall Survival of Patients with Metastatic Castration Resistant Prostate Cancer in a Hospital-based Registry

BACKGROUND: In 2004, docetaxel was shown to prolong the overall survival (OS) of patients with metastatic castration-resistance prostate cancer (mCRPC). Since 2010, five new systemic therapies have been shown to prolong OS in men with mCRPC. We sought to evaluate the aggregate impact of these newer...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Prostate Cancer Prostatic Dis
Main Authors: Francini, Edoardo, Gray, Kathryn P., Shaw, Grace K., Evan, Carolyn P., Hamid, Anis A., Perry, Caitlin E., Kantoff, Philip W., Taplin, Mary-Ellen, Sweeney, Christopher J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7869825/
https://ncbi.nlm.nih.gov/pubmed/30643173
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41391-018-0121-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados